RECURSION PHARMACEUTICALS INC CLAS (RXRX) — insider trading
Health Care · NASDAQ
RECURSION PHARMACEUTICALS INC CLAS (RXRX) has 46 reported SEC Form 4 insider transactions in our data, including 15 open-market sales among the most recent 46 (latest 2026-10-06).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-10-06 | HERSHBERG ROBERT | Director | Option exercise / conversion (derivative) | 25,000 | $2.22 | $55.5K | Form 4 |
| 2026-10-06 | HERSHBERG ROBERT | Director | Open-market sale | 25,000 | $5.00 | $125.0K | Form 4 |
| 2026-10-06 | HERSHBERG ROBERT | Director | Option exercise / conversion | 25,000 | $2.22 | $55.5K | Form 4 |
| 2026-10-06 | Borgeson Blake | Director | Open-market sale | 50,000 | $4.84 | $242.0K | Form 4 |
| 2026-10-01 | Li Dean Y | Director | Grant / award / vesting | 3,378 | — | $0 | Form 4 |
| 2026-10-01 | Dar Zavain | Director | Grant / award / vesting | 4,607 | — | $0 | Form 4 |
| 2026-09-15 | Taylor Ben R | Officer (Chief Financial Officer) | Shares withheld for taxes / exercise cost | 5,396 | $3.41 | $18.4K | Form 4 |
| 2026-09-08 | Khan Najat | Director, Officer (CEO and President) | Open-market sale | 22,408 | $3.52 | $78.8K | Form 4 |
| 2026-09-01 | Borgeson Blake | Director | Open-market sale | 30,000 | $3.34 | $100.2K | Form 4 |
| 2026-08-17 | Taylor Ben R | Officer (Chief Financial Officer) | Shares withheld for taxes / exercise cost | 25,018 | $3.16 | $79.1K | Form 4 |
| 2026-08-17 | Hallett David | Officer (Chief Scientific Officer) | Shares withheld for taxes / exercise cost | 26,657 | $3.16 | $84.2K | Form 4 |
| 2026-08-17 | Khan Najat | Director, Officer (CEO and President) | Shares withheld for taxes / exercise cost | 80,498 | $3.16 | $254.4K | Form 4 |
| 2026-08-04 | Borgeson Blake | Director | Open-market sale | 30,000 | $3.25 | $97.5K | Form 4 |
| 2026-07-07 | Borgeson Blake | Director | Open-market sale | 40,000 | $3.96 | $158.5K | Form 4 |
| 2026-07-01 | Li Dean Y | Director | Grant / award / vesting | 3,747 | — | $0 | Form 4 |
| 2026-07-01 | Dar Zavain | Director | Grant / award / vesting | 5,109 | — | $0 | Form 4 |
| 2026-06-18 | Bumpus Namandje | Director | Open-market sale | 3,963 | $3.18 | $12.6K | Form 4 |
| 2026-06-17 | Bumpus Namandje | Director | Grant / award / vesting | 88,424 | — | $0 | Form 4 |
| 2026-06-17 | Li Dean Y | Director | Grant / award / vesting | 88,424 | — | $0 | Form 4 |
| 2026-06-17 | Dar Zavain | Director | Grant / award / vesting | 88,424 | — | $0 | Form 4 |
| 2026-06-17 | Sun Elaine D | Director | Grant / award / vesting | 88,424 | — | $0 | Form 4 |
| 2026-06-17 | Michor Franziska | Director | Grant / award / vesting | 88,424 | — | $0 | Form 4 |
| 2026-06-17 | HERSHBERG ROBERT | Director | Grant / award / vesting | 88,424 | — | $0 | Form 4 |
| 2026-06-17 | Borgeson Blake | Director | Grant / award / vesting | 88,424 | — | $0 | Form 4 |
| 2026-06-15 | Taylor Ben R | Officer (Chief Financial Officer) | Shares withheld for taxes / exercise cost | 5,396 | $3.15 | $17.0K | Form 4 |
| 2026-06-05 | Khan Najat | Director, Officer (CEO and President) | Open-market sale | 23,588 | $3.58 | $84.5K | Form 4 |
| 2026-06-05 | Gibson Christopher | Director | Conversion of derivative (derivative) | 40,000 | — | $0 | Form 4 |
| 2026-06-05 | Gibson Christopher | Director | Open-market sale | 40,000 | $3.62 | $144.8K | Form 4 |
| 2026-06-05 | Gibson Christopher | Director | Conversion of derivative | 40,000 | — | $0 | Form 4 |
| 2026-06-03 | Bumpus Namandje | Director | Open-market sale | 4,386 | $3.54 | $15.5K | Form 4 |
| 2026-06-02 | Borgeson Blake | Director | Open-market sale | 30,000 | $3.68 | $110.4K | Form 4 |
| 2026-05-22 | Gibson Christopher | Director | Conversion of derivative (derivative) | 40,000 | — | $0 | Form 4 |
| 2026-05-22 | Gibson Christopher | Director | Open-market sale | 40,000 | $3.08 | $123.2K | Form 4 |
| 2026-05-22 | Gibson Christopher | Director | Conversion of derivative | 40,000 | — | $0 | Form 4 |
| 2026-05-15 | Gibson Christopher | Director | Shares withheld for taxes / exercise cost | 22,821 | $3.04 | $69.4K | Form 4 |
| 2026-05-15 | Taylor Ben R | Officer (Chief Financial Officer) | Shares withheld for taxes / exercise cost | 25,018 | $3.04 | $76.1K | Form 4 |
| 2026-05-15 | Khan Najat | Director, Officer (CEO and President) | Shares withheld for taxes / exercise cost | 62,701 | $3.04 | $190.6K | Form 4 |
| 2026-05-15 | Hallett David | Officer (Chief Scientific Officer) | Shares withheld for taxes / exercise cost | 26,657 | $3.04 | $81.0K | Form 4 |
| 2026-05-07 | Gibson Christopher | Director | Conversion of derivative (derivative) | 60,000 | — | $0 | Form 4 |
| 2026-05-07 | Gibson Christopher | Director | Bona fide gift | 20,000 | — | $0 | Form 4 |
| 2026-05-07 | Gibson Christopher | Director | Open-market sale | 40,000 | $3.37 | $134.8K | Form 4 |
| 2026-05-07 | Gibson Christopher | Director | Conversion of derivative | 60,000 | — | $0 | Form 4 |
| 2026-05-05 | Borgeson Blake | Director | Open-market sale | 30,000 | $3.52 | $105.6K | Form 4 |
| 2026-04-22 | Gibson Christopher | Director | Conversion of derivative (derivative) | 40,000 | — | $0 | Form 4 |
| 2026-04-22 | Gibson Christopher | Director | Open-market sale | 40,000 | $3.61 | $144.4K | Form 4 |
| 2026-04-22 | Gibson Christopher | Director | Conversion of derivative | 40,000 | — | $0 | Form 4 |
Ask the chat about RXRX's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: RECURSION PHARMACEUTICALS INC CLAS (RXRX).
Last updated 2026-10-06 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.